A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)
NCT ID: NCT02241772
Last Updated: 2015-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
42 participants
INTERVENTIONAL
2014-09-30
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
NCT06863545
Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity
NCT03351998
Influence of Lipid Lowering on Impaired Coronary Flow
NCT05368545
Lipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
NCT00147602
Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease
NCT00917527
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
10mg TA-8995
10mg TA-8995 once daily
TA-8995
2.5mg TA-8995
2.5mg TA-8995 once daily
TA-8995
Placebo to TA-8995
Placebo to TA-8995 once daily.
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TA-8995
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Abnormal laboratory results (other than lipid levels) or vital signs
* Receiving any other drug therapy
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xention Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Herlev Hospital
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TA-8995-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.